Introduction
One of the key features of an antiviral agent must be to specifically inhibit viral replication and gene expression while leaving cellular metabolism relatively unperturbed. The majority of viruses, however, are dependent upon normal cell gene expression pathways for some stages in their replication and therefore any compound that blocks these stages would of course be toxic to the host cell. Two major goals in antiviral research are therefore to identify suitable targets in the virus life cycle for inhibition and to ensure that the inhibitor displays a high level of specificity.
The global threat posed by human immunodeficiency virus (HIV) has now provided a strong stimulus to extend the potential of antiviral chemotherapy. In order to define new targets for specific inhibition, viral life cycles are being analysed at the detailed molecular level. The information on the structure and function of viral proteins can then be used to specifically design or to screen for small inhibitory molecules. Any virally encoded protein is a potential target for inhibition and the search for anti-HIV agents has now extended beyond attempts to block enzyme activities, such as reverse transcriptase and proteinase (Mitsuya and Broder, 1987) . One major new area of activity is in the definition of viral regulatory proteins as targets for antiviral chemotherapy. Viral regulatory proteins are theoretically excellent targets because they are often virus specific and they are usually essential for viral replication. In this brief review we will describe some of the regulatory proteins of HIV-1 and indicate possible routes to antiviral chemotherapy via inhibition of these requlatory proteins.
The genetic organization of HIV-1
HIV-1 has the basic organization of a retrovirus, with three major genes called gag, pol and env, but in addition there is a complex array of short open reading frames that encode various regulatory proteins. HIV-1 is therefore the most complex retrovirus that has been described to date ( Fig. 1) (Varmus, 1988) . The major structural proteins are the core proteins (GAG proteins), which encapsidate the RNA genome, and the envelope proteins (ENV proteins), which assemble in the cell plasma membrane and envelope the capsids as they mature by budding through the membrane. The major viral enzymes are encoded by the polgene; they are the reverse transcriptase that copies the RNA genome into a double-stranded DNA intermediate that subsequently integrates into the host cell genome, the proteinase that processes the GAG and POL proteins to form mature infectious virions and the integrase that is essential for the integration of the DNA provirus into the cell genome. In addition to the gag, pol and env genes, there are a number of short open reading frames that are known to encode proteins during a viral infection. All of these proteins appear to have some regulatory function in determining the levels of infectious virus (Table 1) . The REV and TAT (Dayton et al., 1986) proteins are both essential for viral replication. The VPU (Cohen et al., 1988) , VPR (Wong-Staal et al., 1987) , NEF and VIF proteins are important but do not appear to be essential for viral replication in model systems, and therefore these ancillary proteins do not represent strong targets for inhibition. In addition, very little is known of the biochemistry and function of VPU, VIF, VPR and NEF (Pavlakis and Felber, 1990) . At present, therefore, the major HIV regulatory proteins that offer realistic targets for inhibition are TAT and REV.
The TAT protein activates viral gene expression by an entirely novel mechanism. It stimulates the production of all viral RNA and also in some way influences their subsequent translation. It appears to function primarily by interacting with an RNA target called TAR. This is a 56 nucleotide sequence that is located at the extreme 5' end of all viral mRNA. The characteristic feature of the TAR sequence is that it can form a very stable stem loop structure (Muesing et al., 1987) . The nucleotide sequence in the stem appears to be less important than the base pairing potential, but the primary sequence of the loop may be critical (Feng and Holland, 1988) 
Inhibition of viral replication via trans-dominant repression
The simplest approach to determining if specific inhibition of regulatory steps can be achieved is to attempt competitive inhibition by using various derivatives of the viral requlator proteins themselves. This has been called parasite-determined resistance (PDR) (Sandford and Johnston, 1985) or trans-dominant repression (TDR) (Herskowitz, 1987 REV and TAT therefore appear to be excellent targets for inhibition as they are both essential for any viral replication. Furthermore, they appear to represent a completely novel class of proteins that has no cellular counterparts. This causes some problems in characterizing the mechanism of action as there are no precedents but it does suggest that any anti-TAT or anti-REV compound might be totally virus specific. Both proteins may have very precise substrate requirements as they appear to interact directly with virus-specific nucleic acid sequences. This suggests that they may have an active site that can be structurally modelled. Finally, both proteins are highly conserved between different viral isolates and are significantly conserved between HIV-1 and HIV-2, suggesting that any inhibitor would be effective in most if not all HIV infections. evidence from micro-injection experiments that TAT functions in the nucleus and interacts with presynthesized RNA to prepare it in some way in the nucleus for its subsequent efficient translation in the cytoplasm (Braddock et el., 1989) . Indirect genetic evidence also indicates that TAT can interact with nascent RNA to stimulate increased transcription of the specific transcription unit (Berkhout et sl., 1989) . The increase in transcription has been proposed to occur at transcription initiation (Gentz et a/., 1989) , transcription elongation (Kao et sl., 1987) or at both initiation and elongation (l.aspia et a/., 1989). There is some preliminary evidence that there is a direct binding interaction between TAT and TAR RNA (Dingwall et el., 1989) , although this has not always been observed (Frankel et a/., 1988a; Gatignol et a/., 1989) . Viruses that are defective in the TAT gene are incapable of replicating and the importance of the TATfTAR interaction for viral replication is further demonstrated by the fact that a 4 bp deletion in the loop of the TAR sequence completely abolishes all viral replication in all cells tested (Leonard et a/., 1989) . Any drug that interfered with TAT action would therefore be a potent inhibitor of viral replication. The REV protein also functions by a novel mechanism. This 113 amino acid protein is known to bind directly to RNA that contains a region of complex secondary structure of about 250 nucleotides, called the REV response element (RRE) (Malim et a/., 1989a; Daly et et., 1989) . The RRE is loated within the second intron region of the genome (Fig. 1b) . This intron must be excised to generate the TAT and REV proteins, but it must be retained and they are organized into multiple functional domains that are in many cases structurally and functionally independent. It is therefore possible to delete or alter one functional domain without significantly disrupting the other(s). The disrupted proteins may then compete with the unaltered, i.e. wild-type, proteins for a particular substrate but are themselves non-functional.
The identification of trans-dominant repressors has been exemplified by studying trans-activator proteins that regulate gene expression by interacting with the DNA in promoter regions. These proteins are often composed of two or three independent functional domains (Keegan et al., 1986) (Fig. 2a) . They either have a domain that interacts directly with a specific short, usually about 8-20bp, DNA sequence or in some cases the protein is targeted to the DNA substrate via a specific interaction with a protein that is already bound at the DNA. In this latter case there is a protein-binding domain rather than a DNA-binding domain. Activator proteins then have a second domain called the activator domain that is responsible for contacting components of the transcription complex, possibly the polymerase itself. In addition many trans-activators
Identifying potential inhibitory domains of HIV-1 regulatory proteins
A first step in determining whether the activity of HIV regulatory proteins TAT and REV can be inhibited has been to locate the key functional domains of the proteins. Genetic analysis of mutant TAT proteins expressed in vivo from mutated genes has defined several possible functional domains (Ruben et al., 1989; Hauber et al., 1989; Kuppuswamy et al., 1989) . Similar results have been obtained using synthetic peptides (Frankel et al., 1989) function -as multimers and specific association domains that mediate dimer formation have been identified. These often display similar features; for example, many transactivators interact via the interdigitation of leucine side chains displayed assymetrically on a helix face, this is called the leucine zipper. DNA binding domains often, but not always, share distinct structural features, for example a helix-tum-helix motif or a zinc finger is common and these can be characterized by conventional biophysical methods and subjected to molecular modelling. Activator domains are in general less well recognizable structurally, but they often display a similar charge distribution with a high density of acidic amino acids (Struhl, 1989) . When the activator protein binds to a recognition site on the DNA, transcription is activated. This is thought to occur when the activation domain contacts components of the transcription initiation complex (Ie; Fig. 2b) .
If the lone DNA or protein-binding domain of an activator protein or a mutant protein that had a defective activator domain were to be expressed in excess in the presence of the normal protein, then the mutant protein would bind to its cognate promoter but fail to function because it lacked an activator domain. The mutant protein would block access of the site to the wild-type protein and effectively block its function, i.e. it would function as a dominant repressor acting in trans (Fig. 2c) . It should be possible to block the replication of a virus by expressing such a trans-dominant derivative of a key viral regulatory protein in the same cell. The feasibility of this approach has been demonstrated against herpes simplex virus (HSV-1). The key regulatory protein VP16 was mutated in the acidic activator domain and cells that constitutively expressed this mutuant protein were refractory to lytic infection by wild-type HSV-1 (Friedman et al., 1988) . Similarly, expression of a the human T-cell leukaemia virus type-II (HTLV-II) trans-activator protein, p3r", that is mutated in the activation domain, inhibits activation of viral gene expression by the wild-type protein (Wachsman et al., 1987) . In theory the substrate-binding domain of any protein that has functionally distinct activation and binding domains can be used as a competitive inhibitor of the wild-type protein. Once a trans-dominant repressor domain has been identified, the next step is to reduce the size of the inhibitory domain. It is possible that a short peptide may be functional, but it is unlikely that a peptide would form the basis of an antiviral, although improvements in cell targeting and drug delivery systems may permit this. The ultimate aim is to model the domain and the smaller the starting point the easier the modelling (Jameson, 1989) . to the nucleus (Hauber et a/., 1989) . A fifth domain is not essential for activity but under some circumstances appears to augment activity. To date over-expression of these domains from gene fragments has not resulted in inhibition of wild-type protein function in the same cell. Similarly, synthetic peptide domains have not functioned as specific competitive inhibitors (Frankel et a/., 1989) . In one study a mutant peptide spanning amino acids 32-67 with a change at amino acid 41 was proposed to function as a competitive inhibitor . This mutation in the entire protein or in fragments when expressed in vivo does not, however, have the same effect. Until these data are repeated it remains possible, therefore, that the chemical synthesis may have generated an artefact.
The fact that it is possible to find some apparently structurally and functionally distinct regions in TAT is encouraging. These do not appear, however, to be large enough to be classified as protein domains. With the exception of the basic region that will target a heterologous protein to the nucleus (Ruben et a/., 1989 ), it has not been possible to show independent function of these regions. With the one exception reported by , it has also not been possible to reproducibly generate a trans-dominant repressor of TAT function. It is not clear, therefore, whether it will be feasible to block TAT action via trans-dominant repression.
There has been significantly more success in inhibiting the action of the REV protein. Various point mutations have been made in REV and two key regions have been identified (Fig.3b) .There is a highly basic region (NOS)that is essential for targeting the protein to the nucleus and nucleolus, and a short, about seven amino acid, region (AS) that is essential for function. This second region may be the active site of the protein. This second class of mutants functions as effective trans-dominant repressors of wild-type REV function, which is consistent with a defect in an activation domain. In addition, expression of these mutant proteins significantly inhibits viral replication in the same cell (Malim et el., 1989a) . To date the nucleic acid binding domain of REVhas not been localized but it is possible that a small peptide may be capable of binding RRE and competitively inhibiting REVfunction. and protein fragments (Braddock et a/., 1989) that are taken up by cells or microinjected. The putative domain structure of the 86 amino acid TAT protein is outlined in Fig. 3a . The amino terminus is essential, it forms an extended 'coil' containing many prolines and a number of acidic amino acids. Alterations in the charge of this region reduces or abolishes TAT activity leading to the suggestion that this is an acidic activation domain. Domain II is a cysteine-rich region; six of the seven cysteines in this region are essential for function. The protein is known to be able to bind zinc or cadmium via these cysteines (Frankel et a/., 1988a) . This region is a candidate nucleic acid-binding region but it does not form a classical zinc finger structure (Miller et a/., 1985; Evans and Hollenberg, 1988) . It is perhaps more likely that it mediates assembly of TAT into dimers or oligomers (Frankel et a/., 1988b) . It is not known whether metal binding or dimer formation is necessary for TAT to function in vivo. Domain III has been poorly studied. It is highly conserved between different isolates and between HIV-1 and HIV-2. Mutations in this region cause reduction or abolition of TAT action. A minimal fragment from amino acids 1-48 is fully functional after direct injection to the nucleus of Xenopus oocytes. This indicates that domains I, II and III are all that are required to constitute a functional protein (Braddock et et., 1989) . However, after expression in the cytoplasm an additional domain, IV, is required to target the TAT protein Modelling regulatory proteins is at present not easy as there are hardly any three-dimensional structures of regulatory proteins on which to base preliminary models. It is also rare to find primary structure homologues. Regulatory proteins are either unique or members of very small families that are often only related via short secondary structure motifs. In the case of the HIV TAT'and REV proteins, .there are no homologues in cells or in other viruses at the primary sequence level. There is, however, a functional homologue of REV. The distantly related retrovirus HTLV-I has the protein REX that also activates the nucleocytoplasmic transport of intron-containing RNA via a response element, RexRE.Interestingly, while there is no sequence homology between REX and REV or between RexRE and RRE the REX protein will function with RRE, although the converse is not true (Rimsky et al., 1989) .Fine structure analysis may ultimately reveal common features in these functionally analogous systems, but these are clearly not obvious at the gross level. To date both REV and TAT have defied attempts at crystallization and TAT produced to date in sufficient bulk for analysis by twodimensional nuclear magnetic resonance spectroscopy (2D-NMR) has not given reliable structural data, possibly due to denaturation and aggregation. The ultimate goal is, however, to define the tertiary structure and much effort is being put into devising new ways of producing large quantities of viral proteins without resorting to denaturation/renaturation steps. Once structural information is available then it should be possible to model isosteric analogues. These small molecules should interact with the substrate, fail to activate and effectively block access of the viral protein. It is of course not necessary to restrict the analysis to mimicking nucleic acid-binding domains. It may be possible to block oligomerization or to block activation by producing a molecule that interacts with the activation target. This approach may, however, be less specific as activation is likely to be effected via a general interaction with cellular factors. When, for example, the lone activation domain of a typical cellular activator is over expressed there is a general repression of all gene expression. This phenomenon has been referred to as 'squelching' (Gill and Ptashne, 1988) . In this case it was thought to be due to the general interaction between any acidic domain with the polymerase effectively removing the available polymerase from the pool. It is possible that TAT and REValso interact with general features of an activation process, not necessarily a polymerase, and therefore any activation domainbased repressor would have a general squelching effect. This has not, however, been shown and if there was a specific interaction between TAT or REV with a cellular protein then this interaction would be a good target for inhibition.
An alternative approach to inhibition is to model the activation target site. In the case of TAT and REVthese are RNA molecules with secondary structures, but in both cases only a small region of secondary structure may be required. It may be possible to construct oligoribonucleotide analogues that block binding.
The classical approach to finding inhibitors of viral regulatory proteins
The identification of trans-dominant repressors, the modelling of active sites and the design of isosteric analogues represent the rational approach to drug development. This approach, while attractive, has still not been exemplified by the production of a clinically useful drug. The more classical and indeed currently proven approach is to use random screening of many thousands of biological and chemical compounds. The understanding and description of TAT and REVfunction derived from the molecular analyses can now be used to design specific and effective screening assays for inhibitors of these proteins. A simple cell-based assay has involved linking the TAR region to reporter genes such as those encoding bacterial or firefly luciferase or bacterial 13-galactosidase or chloramphenicol acetylase. All of these enzymes are readily assayed (e.g. Felber and Pavlakis, 1988) . Expression of the reporter is absolutely dependent upon the interaction of TAT with TAR and therefore inhibitory compounds can readily be scored by the block to reporter gene expression. Similar assays for REV function have been described (Cochrane et al., 1989) . It has proved rather more difficult to devise non-cell based assays for TAT as there has been no convincing demonstration of in vitro activity and the simple binding of TAT to TAR is not sufficiently proven to constitute a reliable assay. It will be extremely difficult to devise an in vitro assay for full REV function as it may involve membrane transport. The binding of REV to its RNA target is, however, well established and therefore assays for compounds that block this binding should prove useful.
Conclusions
The prize for developing inhibitors of either TAT or REVis a rich one. Such compounds would be highly effective because they would totally block all viral replication. They should also display a unique specificity because of the apparently precise interaction between the proteins and their RNAtargets. In addition, because of the conservation between isolates, such inhibitors would be effective against~ny HIV infection. It is also possible that low doses might be used because of the low levels of TAT and REV expression in latently infected cells. There are of course many problems still to be overcome in pursuing the rational design approach. The key problem is the lack of structural information on either REV or TAT. This may be solved by improved production methods to generate homogeneous preparations of native proteins. It will also be important to gain a deeper understanding of the mechanism of action of these two proteins, particularly the TAT protein, which appears to have at least two effects, Le. on transcription and translation, that can be mediated by a 48 amino acid fragment. Understanding the mechanism may have an initial impact upon random screening by allowing the generation of time-saving and specific screens. Ultimately, however, the mechanism of action of any inhibitor must be understood in terms of the molecular interactions between TATfTAR or REVIRRE within the human cell.
